• 1
    Kiselyov A., Balakin K.V., Tkachenko S.E., Savchuk N., Ivachtchenko A.V. (2007) Recent progress in discovey, development of antimitotic agents. Anticancer Agents Med Chem;7:189208.
  • 2
    Blaskó G., Borman L.S., Cordell G.A., Kuehne M.E., Markó I., McCormack J.J., Neuss N., Pearce H.L. (1990) Antitumor bisindole alkaloids from Catharantus roseus (L.). In: BrossiA. editor. The Alkaloids 37. San Diego, CA: Academic Press Inc.; 1240.
  • 3
    Noble R.L., Beer C.T., Cutts J.H. (1958) Role of chance observation in chemotherapy: Vinca Rosea. Ann N Y Acad Sci;76:882894.
  • 4
    Svoboda G.H., Neuss N., Gorman M.J. (1959) Alkaloids of Vinca Rosea Linn. V. Preparation and characterization of alkaloids. J Am Pharm Assoc;48:659666.
  • 5
    Chen S.-H., Hong J. (2006) Novel tubulin-interacting agents: a tale of Taxus brevifolia and Catharantus roseus-based drug discovery. Drugs Future;31:123150.
  • 6
    Guéritte F., Fahy J. (2005) The vinca alkaloids. In: GraggG.M., KingstonD.G.I., NewmanD.J., editors. Anticancer Agents from Natural Products. Boca Raton, FL: Taylor and Francis; p. 123136.
  • 7
    Fahy J. (2001) Modifications in the “upper” velbenamine part of the vinca alkaloids have major implications for tubuline interacting activities. Curr Pharm Des;7:11811197.
  • 8
    Gigant B., Wang C., Ravelli B.G.R., Roussi F., Steinmetz M.O., Curmi P.A., Sobel A., Knossow M. (2005) Structural basis for the regulation of tubuline by vinblastine. Nature;435:519522.
  • 9
    Cormier A., Marchand M., Ravelli R.B.G., Knossow M., Gigant B. (2008) Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep;9:11011106.
  • 10
    Natarajan A., Guo Y., Harbinski F., Fan Y.-H., Chen H., Luus L., Diercks J., Aktas H., Chorev M., Halperin J.A. (2004) Novel arylsulfonamide-oxindole hybrid as an anticancer agent that inhibits translation initiation. J Med Chem;47:49794982.
  • 11
    Ngo Q.A., Roussi F., Cormier A., Thoret S., Knossow M., Guénard D., Guéritte F. (2009) Synthesis and biological evaluation of vinca alkaloids and phomopsin hybrids. J Med Chem;52:134142.
  • 12
    Potier P., Langlois N., Langlois Y., Guéritte F. (1975) Partial synthesis of vinblastine-type alkaloids. J Chem Soc Chem Commun:670671.
  • 13
    Langlois N., Guéritte F., Langlois Y., Potier P. (1976) Application of a modification of the Polonovski reaction to the synthesis of vinblastine-type alkaloids. J Am Chem Soc;98:70177024.
  • 14
    Mangeney P., Andriamialisoa R.Z., Lallemand J.-Y., Langlois N., Langlois Y., Potier P. (1979) 5′-Nor-anhydrovinblastine. Tetrahedron;35:21752179.
  • 15
    Berry R.W., Shelanski M.L. (1972) Interactions of tubulin with vinblastine and guanosine triphosphate. J Mol Biol;71:7180.
  • 16
    Shelanski M.L., Gaskin F., Cantor C.R. (1973) Microtubule assembly in the absence of added nucleotides. Proc Natl Acad Sci U S A;70:765768.
  • 17
    Tempête C., Werner G.H., Favre F., Rojas A., Langlois N. (1995) In vitro cytostatic activity of 9-demethoxyporothramycin B. Eur J Med Chem;30:647650.
  • 18
    Sundberg R.J., Gadamasetti K.G., Hunt P.J. (1992) Mechanistic aspects of the formation of anhydrovinblastine by Potier–Polonovski oxidative coupling of catharantine and vindoline. Spectroscopic observation and chemical reactions of intermediates. Tetrahedron;48:277296.
  • 19
    Mangeney P. (1979) Ph.D. Dissertation. Orsay, France: University Paris-Sud.
  • 20
    Tabakovic I., Ibro E., Gasic M.J. (1996) Anodic C16-C21 fragmentation of catharantine in methanol. Synthesis of 16-methoxycleavamine. J Chem Soc Perkin Trans II;12:27412746.
  • 21
    Andriamialisoa R.Z. (1978) Ph.D. Dissertation. Orsay, France: University Paris-Sud.
  • 22
    Magnus P., Mendoza J.S., Stamford A., Ladlow M., Willis P. (1992) Nonoxydative coupling methodology for the synthesis of the antitumor bisindole alkaloids vinblastine and a lower halg analogue: solvents effect on the stereochemistry of the crucial C-15′/C-18′ bond. J Am Chem Soc;114:1023210245.
  • 23
    Marugan J.J., Manthey C., Anaclerio B., Lafrance L., Lu T., Markotan T., Leonard K.A., Crysler C., Eisennagel S., Dasgupta M., Tomczuk B. (2005) Design, synthesis, and biological evaluation of a novel potent and selective avb3/avb5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core. J Med Chem;48:926934.
  • 24
    Shankaran K., Sloan C.P., Snieckus V. (1985) Synthetic connections to the aromatic directed metalation reaction. Radical-induced cyclisation to substituted benzofurans, benzopyrans and furopyridines. Tetrahedron Lett;50:60016004.
  • 25
    Vukovic J., Goodbody A.E., Kutney J.P., Misawa M. (1988) production of 3′,4′-anhydrovinblastine: a unique chemical synthesis. Tetrahedron;44:325331.
  • 26
    Guéritte F., Pouilhes A., Mangeney P., Andriamialisoa R.Z., Langlois N., Langlois Y., Potier P. (1983) Composés antitumoraux du roupe de la vinblastine: dérivés de la nor-5′anhydrovinblastine. Eur J Med Chem;18:419424.
  • 27
    Kutney J.P., Gregonis D.E., Imhof R., Itoh I., Jahngen E., Scott A.I., Chan W.K. (1975) Absolute stereochemistry of the bisindole alkaloids of the vinblastine type. Circular dichroism studies. J Am Chem Soc;97:50135015.